176 related articles for article (PubMed ID: 15314261)
1. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein.
Morse LJ; Payton SM; Cuny GD; Rogers JT
J Mol Neurosci; 2004; 24(1):129-36. PubMed ID: 15314261
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and dimercaptopropanol.
Payton S; Cahill CM; Randall JD; Gullans SR; Rogers JT
J Mol Neurosci; 2003; 20(3):267-75. PubMed ID: 14501007
[TBL] [Abstract][Full Text] [Related]
3. RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine.
Tucker S; Ahl M; Cho HH; Bandyopadhyay S; Cuny GD; Bush AI; Goldstein LE; Westaway D; Huang X; Rogers JT
Curr Alzheimer Res; 2006 Jul; 3(3):221-7. PubMed ID: 16842099
[TBL] [Abstract][Full Text] [Related]
4. The integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5'-untranslated region.
Venti A; Giordano T; Eder P; Bush AI; Lahiri DK; Greig NH; Rogers JT
Ann N Y Acad Sci; 2004 Dec; 1035():34-48. PubMed ID: 15681799
[TBL] [Abstract][Full Text] [Related]
5. Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease.
Bandyopadhyay S; Cahill C; Balleidier A; Huang C; Lahiri DK; Huang X; Rogers JT
PLoS One; 2013; 8(7):e65978. PubMed ID: 23935819
[TBL] [Abstract][Full Text] [Related]
6. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript.
Rogers JT; Randall JD; Cahill CM; Eder PS; Huang X; Gunshin H; Leiter L; McPhee J; Sarang SS; Utsuki T; Greig NH; Lahiri DK; Tanzi RE; Bush AI; Giordano T; Gullans SR
J Biol Chem; 2002 Nov; 277(47):45518-28. PubMed ID: 12198135
[TBL] [Abstract][Full Text] [Related]
7. A high-throughput drug screen targeted to the 5'untranslated region of Alzheimer amyloid precursor protein mRNA.
Bandyopadhyay S; Ni J; Ruggiero A; Walshe K; Rogers MS; Chattopadhyay N; Glicksman MA; Rogers JT
J Biomol Screen; 2006 Aug; 11(5):469-80. PubMed ID: 16928984
[TBL] [Abstract][Full Text] [Related]
8. Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region.
Rogers JT; Randall JD; Eder PS; Huang X; Bush AI; Tanzi RE; Venti A; Payton SM; Giordano T; Nagano S; Cahill CM; Moir R; Lahiri DK; Greig N; Sarang SS; Gullans SR
J Mol Neurosci; 2002; 19(1-2):77-82. PubMed ID: 12212798
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5' untranslated region.
Tucker S; Ahl M; Bush A; Westaway D; Huang X; Rogers JT
Curr Alzheimer Res; 2005 Apr; 2(2):249-54. PubMed ID: 15974925
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Iron-Response Elements of the mRNAs for the Alzheimer's Amyloid Precursor Protein and Ferritin to Treat Acute Lead and Manganese Neurotoxicity.
Rogers JT; Xia N; Wong A; Bakshi R; Cahill CM
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823541
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis.
Bandyopadhyay S; Rogers JT
Biochem Pharmacol; 2014 Apr; 88(4):486-94. PubMed ID: 24513321
[TBL] [Abstract][Full Text] [Related]
12. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease.
Reznichenko L; Amit T; Zheng H; Avramovich-Tirosh Y; Youdim MB; Weinreb O; Mandel S
J Neurochem; 2006 Apr; 97(2):527-36. PubMed ID: 16539659
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of amyloid precursor protein by peptide nucleic acid in vivo.
Boules M; Williams K; Gollatz E; Fauq A; Richelson E
J Mol Neurosci; 2004; 24(1):123-8. PubMed ID: 15314260
[TBL] [Abstract][Full Text] [Related]
14. Physiological and pathological aspects of Abeta in iron homeostasis via 5'UTR in the APP mRNA and the therapeutic use of iron-chelators.
Avramovich-Tirosh Y; Amit T; Bar-Am O; Weinreb O; Youdim MB
BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S2. PubMed ID: 19090990
[TBL] [Abstract][Full Text] [Related]
15. Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.
Rockenstein E; Torrance M; Mante M; Adame A; Paulino A; Rose JB; Crews L; Moessler H; Masliah E
J Neurosci Res; 2006 May; 83(7):1252-61. PubMed ID: 16511867
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide.
Utsuki T; Yu QS; Davidson D; Chen D; Holloway HW; Brossi A; Sambamurti K; Lahiri DK; Greig NH; Giordano T
J Pharmacol Exp Ther; 2006 Aug; 318(2):855-62. PubMed ID: 16690718
[TBL] [Abstract][Full Text] [Related]
17. Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator.
Bandyopadhyay S; Huang X; Cho H; Greig NH; Youdim MB; Rogers JT
J Neural Transm Suppl; 2006; (71):237-47. PubMed ID: 17447434
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Abeta production by NF-kappaB inhibitors.
Paris D; Patel N; Quadros A; Linan M; Bakshi P; Ait-Ghezala G; Mullan M
Neurosci Lett; 2007 Mar; 415(1):11-6. PubMed ID: 17223266
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the APP proximal promoter and 5'-untranslated regions: identification of cell type-specific domains and implications in APP gene expression and Alzheimer's disease.
Lahiri DK; Ge YW; Maloney B
FASEB J; 2005 Apr; 19(6):653-5. PubMed ID: 15703276
[TBL] [Abstract][Full Text] [Related]
20. The novel multitarget iron chelating and propargylamine drug M30 affects APP regulation and processing activities in Alzheimer's disease models.
Amit T; Bar-Am O; Mechlovich D; Kupershmidt L; Youdim MBH; Weinreb O
Neuropharmacology; 2017 Sep; 123():359-367. PubMed ID: 28571715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
